Drugs / Enterovirus Type 71 Vaccine（Vero Cell）, Inactivated
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT07505836 | Mar 2026 → Jan 2027 expected | meningococcal meningitis | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07505888 | Mar → Nov 2026 expected | meningitis, meningococcal infection | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05397587 | Jul 2022 → Jul 2025 | hand, foot and mouth disease | Sinovac Biotech Co., Ltd | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06734832 Comparator | Dec 2024 → Nov 2025 overdue | hand, foot and mouth disease | Sinovac Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enterovirus Type 71 Vaccine（Vero Cell）, Inactivated | “Enterovirus Type 71 Vaccine（Vero Cell）, Inactivated” NCT05397587 ↗ |
| Known as | experimental vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07505888 ↗ |
| Modality | Vaccine | “Inactivated Vaccine” NCT05397587 ↗ |
| Route | Intramuscular | “the rest of the participants complete the full vaccination through intramuscular injection on the deltoid muscle of the upper arm” NCT06734832 ↗ |